Recurrent Waldenstrom Macroglobulinemia

Explore clinical trials studying Recurrent Waldenstrom Macroglobulinemia. Study availability and eligibility vary by location and protocol.

7 public trials 1 recruiting study

Refine in advanced search Browse all conditions

Recurrent Waldenstrom Macroglobulinemia trial results

Recruiting

Q702 for the Treatment of Patients With Hematologic Malignancies

NCT06712810

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm, Blood Protein Disorders, Bone Marrow Diseases, +87 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Not Yet Recruiting

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

NCT07420959

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations: Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

NCT02332980

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +48 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Completed

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

NCT01381692

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +38 more
Locations: Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States

Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

Hackensack University Medical Center Hackensack, New Jersey, United States

View Trial Details

Completed

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT02950220

Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +46 more
Locations: Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Active, Not Recruiting

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

NCT03147885

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Diffuse Large B-cell Lymphoma, +35 more
Locations: Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States

View Trial Details

Active, Not Recruiting

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

NCT03015896

Conditions: Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +42 more
Locations: Emory University Atlanta, Georgia, United States

Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Recurrent Waldenstrom Macroglobulinemia

Recurrent Waldenstrom Macroglobulinemia trial results

Q702 for the Treatment of Patients With Hematologic Malignancies

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Related conditions